|drug1291||convalescent plasma Wiki||0.58|
|drug865||Placebo oral tablet Wiki||0.20|
|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
|D018352||Coronavirus Infections NIH||0.05|
There is one clinical trial.
This is a double-blind, randomized, placebo-controlled clinical trial. A total of 210 individuals aged over 18 years old, without a diagnosis of severe respiratory disease, who came to the study site with clinical and radiological suspicion of SARS-CoV2, will be randomized into two treatment groups at a 1:1 ratio to receive a 5-day CQ diphosphate tablets or placebo (tablet without active ingredient produced with the same physical characteristics).
Description: Evaluate if CQ diphosphate prevents the onset of SARS in patients on intervention group through standardized questionnaires.Measure: Proportion of patients with onset of severe acute respiratory syndrome (SARS) Time: 7 days after randomization
Description: Mortality rate between intervention and placebo group on days 7, 14, and 28 after randomizationMeasure: Mortality rate Time: after randomization, up to 28 days
Description: Proportion of participants in need and duration of intensive care support after randomizationMeasure: Number of participants in need of intensive care support Time: during and after intervention, up to 28 days
Description: Viral load change in blood and oropharyngeal swab samplesMeasure: Viral concentration Time: After randomization, up to 7 days
Description: Incidence of serious adverse events during and after treatmentMeasure: Cumulative incidence of serious adverse events Time: During and after intervention, up to 28 days
Description: Incidence of grade 3 and 4 adverse events during and after treatmentMeasure: Cumulative incidence of grade 3 and 4 adverse events Time: During and after intervention, up to 28 days
Description: proportion of discontinuation or temporary suspension of treatment (for any reason)Measure: Proportion of patients with discontinued treatment Time: after randomization, up to 28 days
Description: proportion of patients with increased levels of troponin IMeasure: Incidence of cardiac lesions Time: after randomization, up to 120 days
Description: proportion and magnitude of QTcF interval increases higher than 500msMeasure: Incidence of cardiac disfunctions Time: after randomization, up to 120 days
Description: Changes measured on day 120 will be compared to baseline, through spirometry.Measure: Change in respiratory capacity Time: Day 120 after randomization